Login Register Cart 0
Generic placeholder image

Current Chinese Chemistry

Editor-in-Chief

ISSN (Print): 2666-0016
ISSN (Online): 2666-0008

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Stability Indicating Assay Method for the Determination of Febuxostat by RP-HPLC

Author(s): Ramanlal N. Kachave*, Pragati B. Mandlik and Akshay G. Mundhe

Volume 2, Issue 1, 2022

Published on: 27 April, 2021

Article ID: e270421193051 Pages: 9

DOI: 10.2174/2666001601666210427114547

Price: $65

Abstract

Objective: A simple, rapid, precise and accurate RP-HPLC stability indicating method was developed and validated for the estimation of Febuxostat in bulk drug and marketed tablet formulation.

Methods: The chromatographic separation was achieved on Agilent C18 (250 x 4.6 mm, 5 μm) using solvent 15 mM ammonium acetate buffer (pH 4.8) and acetonitrile (30:70 v/v) as a mobile phase at flow rate of 1 mL/min and ambient column temperature analysis were carried out at detection wavelength of 315 nm.

Results: The method was validated for linearity, precision, accuracy, specificity, LOD and LOQ, and robustness. The linearity was studied in the concentration range of 5-25 μg/mL and correlation coefficient was found to be 0.999. The limit of detection and the limit of quantitation were found to be 0.37 μg/mL and 1.13 μg/mL. Febuxostat was subjected to stress conditions of degradation, including acidic, alkaline, oxidation, photolytic and thermal degradation. Febuxostat is more sensitive toward acidic condition than oxidation and less sensitive towards alkaline, thermal and photolytic degradation.

Conclusion: The method is simple, reliable, sensitive and precise, which could separate the drug and their degraded product formed under various stress conditions; thus it can be employed as stability-indicating method for the determination of FBX in bulk and pharmaceutical dosage form.

Keywords: Febuxostat, stability indicating, RP-HPLC, linearity, precise, degradation.

Graphical Abstract

[1]
Stamp, L.K.; O’Donnell, J.L.; Chapman, P.T. Emerging therapies in the long-term management of hyperuricaemia and gout. Intern. Med. J., 2007, 37(4), 258-266.
[http://dx.doi.org/10.1111/j.1445-5994.2007.01315.x] [PMID: 17388867]
[2]
Love, B.L.; Barrons, R.; Veverka, A.; Snider, K.M. Urate-lowering therapy for gout: Focus on febuxostat. Pharmacotherapy, 2010, 30(6), 594-608.
[http://dx.doi.org/10.1592/phco.30.6.594] [PMID: 20500048]
[3]
James, E. Febuxostat: A Review of its use in the treatment of Hyperuricaemia in patient with Gout. Aids Drug Evaluation, 2015, 75(4), 427-438.
[4]
Musirike, M.R.; Hussain Reddy, K.; Mallu, U.R. Development and validation of reverse phase-ultra performance liquid chromatographic method for estimation of related substances in febuxostat drug substance. Pharm. Anal. Acta, 2015, 6, 431.
[http://dx.doi.org/10.4172/2153-2435.1000431]
[5]
Kadivar, M.H.; Sinha, P.K.; Kushwah, D.; Jana, P.; Sharma, H.; Bapodra, A. Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique. J. Pharm. Biomed. Anal., 2011, 56(4), 749-757.
[http://dx.doi.org/10.1016/j.jpba.2011.07.039] [PMID: 21840659]
[6]
Abdul, M.A.; Atul, S.; Prashant, K.; Gaurav, U.; Firoz, A.; Rishabh, S. Validation of a statistically optimized stability indicating method for the estimation of febuxostat in a solid dosage form; EC Pharm. Sci, 2015, pp. 130-144.
[7]
Mathrusri, A.M.; Pavan, S.; Kumar, B.; Venkatesh, B.; Chitaranjan, M. Development and Validation of a Stability- Indication RP-HPLC. Method Determination Febuxostat. J. Chroma. Sci., 2013, 51, 931-938.
[http://dx.doi.org/10.1093/chromsci/bms192]
[8]
Desari, J.; Patel, V. Development and validation of stability indicating LC-PDA method for simultaneous assessment of Febuxostat and Ketorolac Tromethamine in tablet dosage from. Asian J. Chem., 2017, 29, 69-75.
[http://dx.doi.org/10.14233/ajchem.2017.20134]
[9]
Sekhar, R.; Nallagatla, B. A stability indicating RP-HPLC method development for determination of Febuxostat in tablet dosage form. Carib. J. Sci. Tech., 2013, 1, 228-237.
[10]
Balaji, N.; Sayeeda, S. Ultra-high performance liquid chromatographic determination of genotoxic impurities in Febuxostat drug substance and products. Asian. J. Phar. Clin. Res., 2017, 10(1), 324-330.
[11]
Chandra Reddy, M.; Chandra Sekhar, K. Estimation of related substance of Febuxostat in bulk and tablet by RP-HPLC. Int. J. Pharm. Bio. Chem. Sci. (Camb.), 2012, 1(2), 1-10.
[12]
Fawzi, A High-performance thin-layer chromatographic methods for the determination of febuxostate and febuxostate/ diclofenac combination in human plasma.
[13]
Bishoy, K.; Kenneth, M.; Williams, G.; Graham, G.; Ross, L.G.; Norris, S.L.; Stocker Jane, E.C.; Kevin, D.P.; Richard, O.D. Determination of febuxostate in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2019, 1126-1127, 121764.
[14]
Xiea, H.; Zhijun, W.B.; Denga, K.; Xuehua, J.; Ling, W.; Lvc, G. An HPLC–MS/MS method for simultaneous determination of the active metabolites of febuxostate (67M-1, 67M-2 and 67M-4) in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2014, 970, 24-30.
[http://dx.doi.org/10.1016/j.jchromb.2014.08.038] [PMID: 25222745]
[15]
ICH Stability testing of new drug substance and products Q1A (R2). International conference on harmonization, Food and drug administration, USA, 2003.
[16]
ICH Validation of analytical procedure Q2 (R1). International conference on harmonization, Food and drug administration, USA, 1995.

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy